[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522888":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TIL injection treatment group","EXPERIMENTAL",null,[13],"Biological: TIL injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","TIL injection","Autologous tumor infiltrating lymphocyte injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Zhengxiang Han, PHD","CONTACT","+86 18052268612","cnhzxyq@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"The Affiliated Hospital of Xuzhou Medical University","RECRUITING","Xuzhou","Jiangsu","221000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],117.28386,34.20442,{"lat":39,"lon":38},[42,43],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"name":44,"role":45,"phone":11,"phoneExt":11,"email":11},"Zhengxiang Han","PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[49],{"name":28,"class":50},"OTHER","100522888","phase-1-til-injection-for-the-treatment-of-metastatic-or-recurrent-solid-tumors-100522888",false,"NCT06088472","TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","Inclusion Criteria:\n\n* 1\\. Voluntarily participate in the study, sign the informed consent form, and be willing and able to follow the study protocol ;\n* 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor;\n* 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies, and at least tissue blocks with a volume of≥0.5 cubic centimeter (either of single lesion origin or multiple lesions combined) can be isolated for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible;\n\nExclusion Criteria:\n\n* 1\\. Patients who have symptomatic and\u002For untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence);\n* 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\\>10 mg\u002Fday of prednisone or equivalent hormone) within 14 days before lymphocyte depletion chemotherapy;\n* 3\\. Arterial\u002Fvenous thrombotic events within 6 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;\n* 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever \\> 38.5℃ occurring during the screening period, except for tumor fever;\n* 5\\. Patients who have refractory or intractable epilepsy, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications;\n* 6\\. Patients who have received allogeneic bone marrow transplantation or an organ allograft;\n* 7.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);","ALL","18 Years","70 Years",{"count":62,"type":63},12,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.",[69],"Solid Tumors, Adult","2025-09-23",{"date":72,"type":73},"2025-09-29","ACTUAL",{"date":75,"type":73},"2021-04-21",{"date":77,"type":63},"2027-12-31",{"name":5,"class":6},1]